AAPL345.97+2.06 (+0.60%) ▲|ABBV286.81+0.07 (+0.02%) ▲|ABT104.13-0.76 (-0.72%) ▼|ACN236.65-10.58 (-4.28%) ▼|ADBE249.57-9.05 (-3.50%) ▼|AMAT395.82+8.23 (+2.12%) ▲|AMD559.85+28.57 (+5.38%) ▲|AMGN446.95+2.32 (+0.52%) ▲|AMT183.14-5.15 (-2.73%) ▼|AMZN254.04+4.95 (+1.99%) ▲|AVGO341.92+12.75 (+3.87%) ▲|AXP313.40-1.66 (-0.53%) ▼|BA170.20-18.11 (-9.62%) ▼|BAC50.71+0.19 (+0.37%) ▲|BKNG150.71-2.44 (-1.59%) ▼|BLK1,131.37+3.71 (+0.33%) ▲|BMY61.29-0.32 (-0.52%) ▼|BNY147.72+0.54 (+0.37%) ▲|BRK-B545.02-3.54 (-0.65%) ▼|C122.68+1.64 (+1.35%) ▲|CAT713.23+21.10 (+3.05%) ▲|CL92.06-1.05 (-1.12%) ▼|CMCSA21.81-0.25 (-1.11%) ▼|COF204.16+1.81 (+0.89%) ▲|COP148.20-3.18 (-2.10%) ▼|COST992.04-13.12 (-1.31%) ▼|CRM241.95-5.66 (-2.29%) ▼|CSCO111.53+1.29 (+1.17%) ▲|CVS91.35-1.18 (-1.28%) ▼|CVX229.08-2.93 (-1.26%) ▼|DE639.64-1.61 (-0.25%) ▼|DHR232.12-0.85 (-0.36%) ▼|DIS109.86-0.54 (-0.49%) ▼|DUK124.10-0.34 (-0.27%) ▼|EMR165.60+3.90 (+2.41%) ▲|FDX307.15+6.57 (+2.19%) ▲|GD355.10-1.94 (-0.54%) ▼|GE298.08+9.65 (+3.35%) ▲|GEV887.49+32.87 (+3.85%) ▲|GILD157.94-0.75 (-0.47%) ▼|GM80.55+4.24 (+5.56%) ▲|GOOG318.30+4.11 (+1.31%) ▲|GOOGL321.90+5.10 (+1.61%) ▲|GS911.91+18.63 (+2.09%) ▲|HD318.79-0.59 (-0.18%) ▼|HON217.61-1.67 (-0.76%) ▼|IBM250.38-3.07 (-1.21%) ▼|INTC93.38+2.91 (+3.21%) ▲|INTU326.19-13.70 (-4.03%) ▼|ISRG446.61-5.02 (-1.11%) ▼|JNJ268.49+2.19 (+0.82%) ▲|JPM336.16+2.12 (+0.63%) ▲|KO91.65-1.05 (-1.13%) ▼|LIN507.11-0.45 (-0.09%) ▼|LLY1,281.29+2.15 (+0.17%) ▲|LMT623.94-11.26 (-1.77%) ▼|LOW197.99-0.23 (-0.12%) ▼|LRCX240.52+3.02 (+1.27%) ▲|MA607.95-5.55 (-0.90%) ▼|MCD249.67-1.17 (-0.46%) ▼|MDLZ62.05-0.93 (-1.47%) ▼|MDT94.36-0.43 (-0.45%) ▼|META622.57-8.00 (-1.27%) ▼|MMM171.83-0.96 (-0.56%) ▼|MO73.35-0.28 (-0.37%) ▼|MRK142.18+1.57 (+1.12%) ▲|MS187.39+3.90 (+2.13%) ▲|MSFT531.20-1.40 (-0.26%) ▼|MU931.47+27.77 (+3.07%) ▲|NEE82.19+0.15 (+0.18%) ▲|NFLX62.71-1.20 (-1.87%) ▼|NKE37.44-0.48 (-1.25%) ▼|NOW155.64-2.54 (-1.61%) ▼|NVDA217.78+1.78 (+0.82%) ▲|ORCL131.60+5.54 (+4.39%) ▲|PEP132.66-2.80 (-2.07%) ▼|PFE29.75-0.05 (-0.15%) ▼|PG158.98-0.94 (-0.59%) ▼|PLTR199.44+0.60 (+0.30%) ▲|PM203.18+1.31 (+0.65%) ▲|QCOM181.79+2.19 (+1.22%) ▲|RTX195.29-2.20 (-1.11%) ▼|SBUX102.52-0.18 (-0.17%) ▼|SCHW89.62-0.11 (-0.12%) ▼|SO92.14-0.44 (-0.47%) ▼|SPG211.92-0.77 (-0.36%) ▼|T20.98+0.13 (+0.60%) ▲|TMO698.34+13.45 (+1.96%) ▲|TMUS147.04+0.11 (+0.07%) ▲|TSLA406.03+14.41 (+3.68%) ▲|TXN307.36+9.24 (+3.10%) ▲|UBER65.90-0.24 (-0.36%) ▼|UNH409.45-1.25 (-0.30%) ▼|UNP299.26+2.29 (+0.77%) ▲|UPS105.72+5.40 (+5.38%) ▲|USB59.77+0.07 (+0.11%) ▲|V398.62-5.54 (-1.37%) ▼|VZ43.79+0.69 (+1.59%) ▲|WFC82.76+0.11 (+0.13%) ▲|WMT118.96-1.34 (-1.11%) ▼|XOM180.97-3.57 (-1.93%) ▼|AAPL345.97+2.06 (+0.60%) ▲|ABBV286.81+0.07 (+0.02%) ▲|ABT104.13-0.76 (-0.72%) ▼|ACN236.65-10.58 (-4.28%) ▼|ADBE249.57-9.05 (-3.50%) ▼|AMAT395.82+8.23 (+2.12%) ▲|AMD559.85+28.57 (+5.38%) ▲|AMGN446.95+2.32 (+0.52%) ▲|AMT183.14-5.15 (-2.73%) ▼|AMZN254.04+4.95 (+1.99%) ▲|AVGO341.92+12.75 (+3.87%) ▲|AXP313.40-1.66 (-0.53%) ▼|BA170.20-18.11 (-9.62%) ▼|BAC50.71+0.19 (+0.37%) ▲|BKNG150.71-2.44 (-1.59%) ▼|BLK1,131.37+3.71 (+0.33%) ▲|BMY61.29-0.32 (-0.52%) ▼|BNY147.72+0.54 (+0.37%) ▲|BRK-B545.02-3.54 (-0.65%) ▼|C122.68+1.64 (+1.35%) ▲|CAT713.23+21.10 (+3.05%) ▲|CL92.06-1.05 (-1.12%) ▼|CMCSA21.81-0.25 (-1.11%) ▼|COF204.16+1.81 (+0.89%) ▲|COP148.20-3.18 (-2.10%) ▼|COST992.04-13.12 (-1.31%) ▼|CRM241.95-5.66 (-2.29%) ▼|CSCO111.53+1.29 (+1.17%) ▲|CVS91.35-1.18 (-1.28%) ▼|CVX229.08-2.93 (-1.26%) ▼|DE639.64-1.61 (-0.25%) ▼|DHR232.12-0.85 (-0.36%) ▼|DIS109.86-0.54 (-0.49%) ▼|DUK124.10-0.34 (-0.27%) ▼|EMR165.60+3.90 (+2.41%) ▲|FDX307.15+6.57 (+2.19%) ▲|GD355.10-1.94 (-0.54%) ▼|GE298.08+9.65 (+3.35%) ▲|GEV887.49+32.87 (+3.85%) ▲|GILD157.94-0.75 (-0.47%) ▼|GM80.55+4.24 (+5.56%) ▲|GOOG318.30+4.11 (+1.31%) ▲|GOOGL321.90+5.10 (+1.61%) ▲|GS911.91+18.63 (+2.09%) ▲|HD318.79-0.59 (-0.18%) ▼|HON217.61-1.67 (-0.76%) ▼|IBM250.38-3.07 (-1.21%) ▼|INTC93.38+2.91 (+3.21%) ▲|INTU326.19-13.70 (-4.03%) ▼|ISRG446.61-5.02 (-1.11%) ▼|JNJ268.49+2.19 (+0.82%) ▲|JPM336.16+2.12 (+0.63%) ▲|KO91.65-1.05 (-1.13%) ▼|LIN507.11-0.45 (-0.09%) ▼|LLY1,281.29+2.15 (+0.17%) ▲|LMT623.94-11.26 (-1.77%) ▼|LOW197.99-0.23 (-0.12%) ▼|LRCX240.52+3.02 (+1.27%) ▲|MA607.95-5.55 (-0.90%) ▼|MCD249.67-1.17 (-0.46%) ▼|MDLZ62.05-0.93 (-1.47%) ▼|MDT94.36-0.43 (-0.45%) ▼|META622.57-8.00 (-1.27%) ▼|MMM171.83-0.96 (-0.56%) ▼|MO73.35-0.28 (-0.37%) ▼|MRK142.18+1.57 (+1.12%) ▲|MS187.39+3.90 (+2.13%) ▲|MSFT531.20-1.40 (-0.26%) ▼|MU931.47+27.77 (+3.07%) ▲|NEE82.19+0.15 (+0.18%) ▲|NFLX62.71-1.20 (-1.87%) ▼|NKE37.44-0.48 (-1.25%) ▼|NOW155.64-2.54 (-1.61%) ▼|NVDA217.78+1.78 (+0.82%) ▲|ORCL131.60+5.54 (+4.39%) ▲|PEP132.66-2.80 (-2.07%) ▼|PFE29.75-0.05 (-0.15%) ▼|PG158.98-0.94 (-0.59%) ▼|PLTR199.44+0.60 (+0.30%) ▲|PM203.18+1.31 (+0.65%) ▲|QCOM181.79+2.19 (+1.22%) ▲|RTX195.29-2.20 (-1.11%) ▼|SBUX102.52-0.18 (-0.17%) ▼|SCHW89.62-0.11 (-0.12%) ▼|SO92.14-0.44 (-0.47%) ▼|SPG211.92-0.77 (-0.36%) ▼|T20.98+0.13 (+0.60%) ▲|TMO698.34+13.45 (+1.96%) ▲|TMUS147.04+0.11 (+0.07%) ▲|TSLA406.03+14.41 (+3.68%) ▲|TXN307.36+9.24 (+3.10%) ▲|UBER65.90-0.24 (-0.36%) ▼|UNH409.45-1.25 (-0.30%) ▼|UNP299.26+2.29 (+0.77%) ▲|UPS105.72+5.40 (+5.38%) ▲|USB59.77+0.07 (+0.11%) ▲|V398.62-5.54 (-1.37%) ▼|VZ43.79+0.69 (+1.59%) ▲|WFC82.76+0.11 (+0.13%) ▲|WMT118.96-1.34 (-1.11%) ▼|XOM180.97-3.57 (-1.93%) ▼|
14.6 C
New York
Tuesday, October 27, 2026

Tag: trials

newsFORsourcecompanycontentinformation1releasesmarket

Rooted, a Collaboration with ReLeaf Shop, Celebrates Grand Opening Friday, Oct. 30 in Eldersburg

Veteran-founded partnership brings Baltimore's ReLeaf Shop to Carroll CountyELDERSBURG, Md., Oct. 27, 2026 /PRNewswire/ -- Rooted, a collaboration with ReLeaf Shop, will celebrate its...

Atrium Therapeutics Doses First Patient in Corventis™, the First Interventional Clinical Trial for People Living with PRKAG2 Syndrome

-- Global Phase 1/2 trial will evaluate ATR 1072 in approximately 37 participants ---- Initial proof of concept data expected in second half of...

National Leader in Cancer Symptom Management, Ishwaria Subbiah, MD, Joins Perlmutter Cancer Center

Dr. Subbiah will expand access to new treatment options while keeping quality of life at the center of care.NEW YORK, Oct. 27, 2026 /PRNewswire/...

Hyundai Hope on Wheels Exceeds National Goal, Committing $4.8 Million for Childhood Cancer Care and Research in Canada

The second year of the Hyundai Hope on Wheels campaign surpassed $4.8 million in donations to 16 hospital foundations across Canada, exceeding its goal...

Riboscience Presents Phase 1a/b Overall Survival Data for ENPP1 Inhibitor RBS2418 as Monotherapy and in Combination Therapy in Advanced Solid Tumors and Late-Line CRC

Median overall survival of 12 months with RBS2418 monotherapy in subjects with heavily pretreated tumors that express ENPP1 and cGAS proteins (TME-EG+ phenotype), versus...

TransCode Therapeutics Presents Phase 1a Clinical Data for TTX-MC138 at ESMO Congress 2026

Poster highlights durable disease control, acceptable tolerability and exploratory evidence of treatment-associated antitumor immune activity in patients with advanced solid tumorsBOSTON, Oct. 26, 2026 /PRNewswire/...

CityUHK researchers reveal how fructose can suppress liver cancer, opening a new therapeutic avenue

HONG KONG, Oct. 26, 2026 /PRNewswire/ -- Fructose is an important nutrient, which despite having a chemical structure very similar to that of glucose,...

Innovent Announces NMPA Acceptance of a New Indication Application of Sintilimab for the Treatment of Advanced Melanoma

SAN FRANCISCO and SUZHOU, China, Oct. 26, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...

CStone Announces Major Clinical Validation Milestone for CS2009 at ESMO 2026: Data from More Than 300 Patients Support Mechanism, Safety and Broad Antitumor Activity

CS2009, an Innovative PD-1/VEGF/CTLA-4 trispecific antibody, demonstrates a differentiated profile through synergistic triple-pathway targeting, favorable tolerability and encouraging efficacy across multiple solid tumorsHighlightsThree pillars...

Fabarta Unveils Major Upgrade to Its AI for Science Platform, Named Among Inaugural “Hong Kong Top Talent Ecosystem Partners” Ahead of Hong Kong FinTech...

Powered by the upgraded RSI engine, the platform unifies data, models, experiments and production to accelerate materials innovationBEIJING, Oct. 26, 2026 /PRNewswire/ -- Fabarta...

2026 ESMO | Innovent Presents Multiple Clinical Data Updates for IBI363/TAK-928, a PD-1/Alpha-Biased IL-2 Bispecific Fusion Protein

The data showcased are from three Phase 1b clinical studies of IBI363/TAK-928 in first-line NSCLC, first-line G/GEJA, and immunotherapy-resistant lung adenocarcinoma, further supporting its...

Tennessee Oncology Researchers Help Lead Global Trial of Next-Generation Lung Cancer Therapy

Research Conducted at Tennessee Oncology's Greco-Hainsworth Centers for Research Contributes to Study Showing Longer Overall Survival with Next-Generation KRAS G12C TherapyNASHVILLE, Tenn., Oct. 25, 2026...

Positive Overall Survival Results from the Phase III HARMONi-GI1 Trial of Ivonescimab Plus Chemotherapy Versus Durvalumab Plus Chemotherapy in First-Line Biliary Tract Cancer Presented...

HONG KONG, Oct. 25, 2026 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926.HK) today announced the presentation of results from the randomized, controlled, double-blind, multicenter, registrational Phase...

New data on Lilly’s investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer

Data presented at ESMO highlight the promising efficacy of olomorasib in combination with standard-of-care immunotherapy with or without chemotherapy in first-line advanced KRAS G12C-mutant...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTrials

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers